Association between peptidylarginine deiminase type 4 rs1748033 polymorphism and susceptibility to rheumatoid arthritis in Zahedan, Southeast Iran

Abstract

Copyright © Spring 2015, Iran J Allergy Asthma Immunol. All rights reserved. There are controversial reports regarding the role of peptidylarginine deiminase type 4 (PADI4) gene polymorphisms and risk of Rheumatoid arthritis (RA). The aim of the present study was to investigate the impact of PADI4 rs1748033 polymorphism and susceptibility to RA in a sample of the Iranian population. This case-control study was done on 150 patients with RA and 150 healthy subjects. PADI4 rs1748033 genotyping was done using amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) assay. The PADI4 rs1748033 variant increased the risk of RA in codominant (OR=1.67, 95%CI=1.03-2.71, p=0.048, CT vs CC; OR=2.73, 95%CI=1.25-5.97, p=0.013, TT vs CC) and dominant (OR=1.84, 95%CI=1.15-2.92, p=0.014, CT+TT vs CC) tested inheritance models. In addition, the PADI4 rs1748033 T allele increased the risk of RA (OR=1.63, 95%CI=1.16-2.29, p=0.006) in comparison with C allele. In conclusion, our finding indicated that PADI4 rs1748033 gene polymorphism increased the risk of RA in a sample of the Iranian population.